Researcher Spotlight: Ayushi Chauhan, MD AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. Stephanie A. Gregory Distinguished Scholar Primary central nervous system lymphoma, or PCNSL, is a rare and aggressive form of non-Hodgkin lymphoma that predominantly affects older adults over the age of…
Researcher Spotlight: Robert Kridel, MD, MPH, PhD UNIVERSITY HEALTH NETWORK, TORONTO Despite therapeutic advances that have transformed the treatment of follicular lymphoma (FL), the disease remains incurable for many patients. Using genomic profiling of tumor samples from large numbers of…
Researcher Spotlight: Arash Alizadeh, MD, PhD Stanford University Although many patients experience profound improvements in disease control with chimeric antigen receptor (CAR) T-cell therapies, not all people with follicular lymphoma (FL) treated with these agents will respond. Using cutting edge…
Researcher Spotlight: Wendy Béguelin, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Follicular lymphoma (FL) is a clinically heterogenous disease. For some patients, tumors are slow growing and outcomes are favorable; others experience a high-risk, rapidly progressing disease that is associated…
Researcher Spotlight: Matthew Maurer, D.M.Sc MAYO CLINIC, ROCHESTER Follicular lymphoma (FL) is a heterogeneous disease characterized by episodes of relapse and transformation. Prognostic models exist that can be applied at diagnosis to predict how the disease will progress and what…
Researcher Spotlight: Joshua Brody, MD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies, have revolutionized the treatment of follicular lymphoma (FL), but many patients still relapse. Antigen escape is…
Researcher Spotlight: Edward Dominguez, PhD BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE HEALTH EQUITY INITIATIVE Cyclin-dependent kinases, including CDK9, are responsible for regulation of a variety of cellular processes that contribute to the growth and expansion of cancer cells. Using…
Researcher Spotlight: Ajlan Al Zaki, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by…
Researcher Spotlight: Christopher Sauter, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T-cell therapies work by harnessing the power of T cells to kill lymphoma cells through a variety of cytotoxic mechanisms that are coordinated simultaneously.…
Researcher Spotlight: Yifei Liao, PhD BRIGHAM AND WOMEN’S HOSPITAL Several types of lymphomas have been associated with Epstein-Barr virus (EBV) infection. Little is known about how EBV manipulates cellular processes in lymphoma, though, including how it evades detection by the…